Alphabet’s venture capital arm GV led a $58.5 million investment to launch Verve Therapeutics, a new biotech focused on developing therapies that edit the human genome to treat heart diseases.

Merck & Co. has apparently gotten excited again about pushing the frontier with new RNA-based therapies. MRL Ventures, Merck’s early-stage biotech investment arm, has agreed to join The Baupost Group in leading a $55 million Series B venture investment in Cambridge, Mass.-based RaNA Therapeutics. The round included a handful of “crossover” investors that usually focus […]